Anavex Life Sciences shares are trading higher after the company presented its new data from its AD-004 phase IIb/III trial at the AD/PD 2026 conference demonstrating consistent correlation between the treatment effect of oral blarcamesine and preservation of brain volume in early alzheimer's disease.